Manu De RyckerDavid HornBree AldridgeRichard K. AmewuClifton E. BarryFrederick S. BucknerSarah CookMichael A.J. FergusonNathalie GobeauJennifer HerrmannPaul HerrlingWilliam HopeJennifer KeiserMaria Jose Lafuente-MonasterioPaul D. LeesonDidier LeroyUjjini H. ManjunathaJames McCarthyTimothy J. MilesValerie MizrahiOlena MoshynetsJacquin NilesJohn P. OveringtonJohn PottageSrinivasa P.S. RaoKevin D. ReadIsabela RibeiroLynn L. SilverJen SouthernThomas SpangenbergShyam SundarCaitlin TaylorWes Van VoorhisNicholas J. WhiteSusan WylliePaul G. WyattIan H. GilbertLancaster Institute for the Contemporary ArtsViiV HealthcareHelmholtz-Institut für Pharmazeutische Forschung Saarland (HIPS)GlaxoSmithKline plc, SpainInstitute of Molecular Biology and Genetics National Academy of Sciences of UkraineBanaras Hindu University, Institute of Medical SciencesQIMR Berghofer Medical Research InstituteUniversitat BaselSwiss Tropical and Public Health Institute (Swiss TPH)Massachusetts Institute of TechnologyUniversity of LiverpoolMerck KGaAUniversity of GhanaNational Institute of Allergy and Infectious DiseasesTufts University School of MedicineUniversity of Washington, SeattleMahidol UniversityHelmholtz Centre for Infection Research (HZI)University of DundeeNovartis Institutes for BioMedical Research, Inc.University of GlasgowUniversity of Cape TownPaul Leeson Consulting Ltd.LL Silver ConsultingMedicines for Malaria VentureDrugs for Neglected Diseases InitiativeMedicines Discovery CatapultIndependent Consultant2020-03-262020-03-262020-01-10ACS Infectious Diseases. Vol.6, No.1 (2020), 3-13237382272-s2.0-85076754483https://repository.li.mahidol.ac.th/handle/20.500.14594/53782© 2019 American Chemical Society. In May 2019, the Wellcome Centre for Anti-Infectives Research (WCAIR) at the University of Dundee, UK, held an international conference with the aim of discussing some key questions around discovering new medicines for infectious diseases and a particular focus on diseases affecting Low and Middle Income Countries. There is an urgent need for new drugs to treat most infectious diseases. We were keen to see if there were lessons that we could learn across different disease areas and between the preclinical and clinical phases with the aim of exploring how we can improve and speed up the drug discovery, translational, and clinical development processes. We started with an introductory session on the current situation and then worked backward from clinical development to combination therapy, pharmacokinetic/pharmacodynamic (PK/PD) studies, drug discovery pathways, and new starting points and targets. This Viewpoint aims to capture some of the learnings.Mahidol UniversityMedicineReviewSCOPUS10.1021/acsinfecdis.9b00371